21st RSC / SCI Medicinal Chemistry Symposium
21st RSC / SCI Medicinal Chemistry Symposium
Monday-Wednesday, 13th-15th September 2021
A virtual event, hosted at Churchill College, Cambridge, UK
Downloads and Links
Online registration – to pay by card
Registration form – to pay by bank transfer
Abstract template – closing date is 23rd July (second round)
Bursary application form – closing date is 30th July
Twitter hashtag – #CamMedChem21
The organisers invite you to the 21st RSC / SCI Medicinal Chemistry Symposium, Europe’s premier biennial Medicinal Chemistry event, focussing on first disclosures and new strategies in Medicinal Chemistry.
Reflecting current trends in medicinal chemistry and pharmaceutical research, the scientific programme will feature lectures on the full range of drug targets, key enabling processes and technologies together with late breaker talks.
Who should attend
This conference will be of interest to both academic and industrial scientists engaged in all aspects of the drug discovery and development process. It will aim to showcase first disclosures of significant new therapeutic agents across all disease areas, and provide a forum for discussion of current topics and thinking at the forefront of medicinal chemistry.
Call for Posters
A number of conference places will be reserved for poster presenters and contributions are invited from the whole field of medicinal chemistry. Those presenting a poster may also elect to advertise their poster via an oral presentation of a single-slide ‘flash’ poster. To enable presenters to receive approval from their institutions, there were early and final submission dates – 30th April and 23rd July 2021. The outcomes of second round applications will be notified in August.
All posters will be displayed online only, even if there were a face-to-face element to the symposium.
Please download the abstract template and send it to the Secretariat in Word format.
Early-career Medicinal Chemistry Workshop
The updated workshop has been developed and facilitated by a cross-industry group of expert medicinal chemists and it will be run either before or after the symposium.
Early career* scientists attending the conference will have the opportunity to apply for a free place on this popular satellite event.
* Early career is defined as five years or fewer of post-graduate experience in medicinal chemistry.
Monday, 13th September
|13.30||Introduction and welcome|
|13.35||Discovery and first structural disclosure of AZD0095, a potent and selective inhibitor of MCT4 for oncology
Frederick Goldberg, AstraZeneca, UK
|14.10||Structure-guided discovery of a potent and selective USP7 inhibitor
András Kotschy, Servier Research Institute of Medicinal Chemistry, HU
|14.45||Lenacapavir: a first-in-class phase 2/3 HIV capsid inhibitor with potential for twice yearly dosing
Jennifer Zhang, Gilead Sciences, US
|15.20||Flash poster presentations - session 1 (ten two-minute presentations)|
|15.40||Posters, networking, exhibitor videos, and refreshments|
|16.40||Translating frontier oncology targets to outsmart cancer™
Elena Koltun, Revolution Medicines, US
|17.15||Discovery of CFTR modulators for the treatment of cystic fibrosis
Jeremy Clemens, Vertex, US
|17.40||Mass spectrometry and its role in drug discovery
Keynote: Dame Carol Robinson, University of Oxford, UK
Tuesday, 14th September
|10.30||Lysine-targeting covalent inhibitors for HSP70 and triple-mutant EGFR: overcoming low druggability and resistance
Matthew Cheeseman, The Institute of Cancer Research, UK
|11.05||Snapshots of cannabinoid receptor 2 agonists on their way to bedside
Uwe Grether, F Hoffmann-La Roche, CH
|11.40||The identification of GPR52 agonist HTL0041178, a potential therapy for schizoaffective and related psychiatric disorders
Steve Watson, Sosei Heptares, UK
|13.15||Presentation of the 2021 Malcolm Campbell Memorial Prize by
Sir Patrick Vallance, Chief Scientific Adviser to the Government of the UK
|13.25||Discovery of selective, CNS-penetrant, reversible Bruton’s Tyrosine Kinase (BTK) inhibitors for the treatment of disease progression in multiple sclerosis
tbc, Biogen, US
|14.00||Discovery of highly soluble inhaled FRAP1 inhibitors with high lung:systemic unbound ratio via application of a novel 3Rs inhaled approach
Heather Hobbs, GlaxoSmithKline, UK
|14.35||Discovery of IRAK4 inhibitors BAY 845 and BAY 839: first disclosure presentation
Ulrich Bothe, Bayer, DE
|15.10||Flash poster presentations - session 2 (ten two-minute presentations)|
|15.30||Posters, networking, exhibitor videos, and refreshments|
|16.30||Discovery of potent, selective and brain-penetrant eIF2B activators for the treatment of neurodegenerative diseases
Maksim Osipov, Denali Therapeutics, US
|17.05||Development of next generation utrophin modulators for Duchenne muscular dystrophy: learning from clinical setbacks
Angela Russell, University of Oxford, UK
|17.40||Medicines for millions
The BMCS Hall of Fame 2020 Inductee: David Rees, Astex Pharmaceuticals, UK
Wednesday, 15th September
|10.30||Design of advanced γ-secretase modulators by co-ordinated structural replacements and a novel bioisostere
Rosa Maria Rodriguez Sarmiento, F Hoffmann-La Roche, CH
|10.50||Small molecule degraders of the estrogen receptor
Thomas Moss, AstraZeneca, UK
|11.25||Advances in small molecules inducing targeted protein degradation
Ian Collins, The Institute of Cancer Research, UK
|11.45||Proteomics based target deconvolution leads to the discovery of PAPD5 as the target of the HBV-antigen inhibitor RG7834
Douglas Thomson, GlaxoSmithKline, DE
|Session 7 - Late-breaking Science|
|13.20||The COVID Moonshot: SARS-CoV-2 oral antiviral therapeutics from an Open Science Global Collaboration
Ed Griffen, MedChemica, UK
|13.40||Oral inhibitors of the SARS-CoV-2 main protease for the treatment of COVID-19
Dafydd Owen, Pfizer Worldwide Research Development and Medicine, US
|14.00||Fragment based discovery of MRTX9768, a selective inhibitor of the PRMT5∙MTA complex for the treatment of MTAP/CDKN2A ̶ deleted tumours
Chris Smith, Mirati Therapeutics, US
|14.35||Discovery of an oral, Ro5 compliant IL17A protein-protein interaction modulator for the treatment of psoriasis
Mark Andrews, LEO Pharma, DK
|15.10||Posters, networking, exhibitor videos, and refreshments|
|15.40||Inhibitors and degraders of the BCL6-co-repressor interaction
Rosemary Huckvale, The Institute of Cancer Research, UK
|16.00||The effect of core replacement on the selective Mcl-1 inhibitor S64315
Márton Csékei, Servier Research Institute of Medicinal Chemistry, HU
|16.20||Advancements in chemistry technologies and chemical biology to enhance the portfolio
Anil Vasudevan, AbbVie, US
|16.55||Inspiring medicinal chemistry with novel multi-objective optimised ideas: the Novartis Generative Chemistry initiative
Finton Sirockin, Novartis, CH
Delegate registration fees for virtual attendance include attendance at the full technical programme. Only one log-in link will be allocated to each registered delegate.
£230 Member* of the RSC or SCI
£115 Student** member, unemployed member, retired member
£135 Student** non-member, unemployed non-member, retired non-member
£1000 Exhibitor Package† – no attendees are included
* Member is a paid-up member of the RSC or SCI
** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students.
† For details of the Package, see the Exhibitor Opportunity Package paragraph below.
Some student bursaries are available – see below.
Format of Symposium
At the time of registration you will be asked whether you would like to be considered for face-to-face participation if the opportunity arose. It is the intent of the Organising Committee to offer in July a limited number of attendances in person for which additional registration fees will be added to the registration fees for virtual attendance. These additional charges below would cover three lunches and refreshments in all of the breaks.
£155 Delegate member
£175 Delegate non-member
£105 Student, unemployed & retired member
£115 Student non-member
If able to proceed with a face-to-face element the Organising Committee will select participants via a ballot* from delegates who have registered for the online event and confirmed that they are permitted to attend in person by their employer, where relevant. Bedrooms may be available in College, and attendees would book these direct with Churchill College.
*Selection of delegates will take diversity of the audience into account.
Want to become a member?
Some student bursaries are available to cover the Student Member registration fee of £115. Applications are invited from PhD and post-doctoral students studying at an academic institution, preferably members of the RSC, SCI or EFMC.
These bursaries are supported by the RSC-BMCS and the SCI. SCI bursaries will only be awarded to those who are SCI members.
The closing date for bursary application is 30th July 2021, and you may download this bursary application form.
The Exhibitor Package is priced at £1,000 and includes:
– Logo and web-link in “all-delegate” pre-event e-mails
– Logo and web-link on Maggi Churchouse Events webpage
– Full promotional page in delegate handbook (web-linked for electronic handbook)
– Logo in rolling slides shown at event
– Logo and web-link in “all-delegate” post-event e-mail.
Additional benefits may be added to this package, especially networking.
Note: no delegate registrations are included with this Exhibitor Package.
Should a physical option become available, further information about exhibitor opportunities will be provided on this page.
Sponsors are encouraged to support Europe’s premier, biennial medicinal chemistry event. We are grateful to our confirmed sponsors: Domainex, Selvita, Hypha Discovery, Evotec, AstraZeneca, Charles River, X-Chem, Vertex and GlaxoSmithKline.
We are grateful to our supporters: EFMC and Marine Drugs Journal
Nadia Ahmad, Charles River
Mark Healy, Novartis (Technical Adviser)
Simon Peace, GlaxoSmithKline (Chair)
Jo Pinder, Vertex
Gordon Saxty, Fidelta (Treasurer)
Jamie Scott, AstraZeneca
Chris Swain, Cambridge MedChem Consulting
Nigel Swain, Sosei Heptares
Andrew Williams, Hon Chairman, RSC BMCS